logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 865 2352511, +7 865 2353229.

E-mail
medvestnik@stgmu.ru

Pineal hormone melatonin as universal modulator of any pathological processes

[Reviews]
Eduard Arushanyan; Evgeny Shchetinin;

description

Download

References:
1. Anisimov V. N. Melatonin: role in the body, clinical use. Sanct Petersburg; 2007. 40 p.
2. Arushanian E. B. Role of pineal gland in brain protection against stress. Adv. Physiol. Sciences. 1996;27:31-50.
3. Arushanian E. B. Complex interrelations hypothalamic suprachiasmatic nuclei with pineal gland and striatum –functionally single system for regulating daily fluctuations of behavior. J. Higher Nerv. Act. 1996;46:15-22.
4. Arushanian E. B. Antistress capacity of pineal melatonin. – Melatonin in norm and pathology. Мoscow:
«Medpractica»; 2004. P. 198-222.
5. Arushanian E. B. Pineal hormone melatonin – a new nootropic drug? Exp. and Clin. Pharmacol. 2005;68(3):74-79.
6. Arushanian E. B. Unique melatonin. Stavropol; 2006. 399 p.
7. Arushanian E. B. Protective role of melatonin in brain circulation disturbances. Rus. Med. J. 2010;18:57-61.
8. Arushanian E. B. Melatonin and Alzheimer’s disease. J. Neurol. and Psychiat. 2010;110:100-106.
9. Arushanian E. B. Hormonal drug melatonin for treating cognitive disorders in parkinsonism. Exp. and Clin. Pharmacol. 2010;73(3):35-39.
10. Arushanian E. B. Melatoninergic antidepressant Valdoxan. Exp. and Clin. Pharmacol. 2011;74(3):41-45.
11. Arushanian E. B. Melatonin – universal stabilizer of mental activity. J. Higher Nerv. Act. 2011;61:645-659.
12. Arushanian E. B. Pineal hormone melatonin in combined pharmacotherapy different brain disorders and somatic pathology. Exp. and Clin. Pharmacol. 2011;74(9):39-45.
13. Arushanian E. B. Protective role of melatonin in pancreas disorders. Exp. and Clin. Pharmacol. 2012;75(4):42-48.
14. Arushanian E. B. Melatonin and diabetes. – Melatonin: potential use in clinical practice. Мoscow: «Imapress»; 2012. P. 30-39.
15. Arushanian E. B. Limitation oxidative stress as the main reason for universal protective features of melatonin. Exp. and Clin. Pharmacol. 2012;75(5):44-49.
16. Arushanian E. B. Analgesia and pineal hormone melatonin. Exp. and Clin. Pharmacol. 2012;75(8):44-48.
17. Arushanian E. B. Pregnancy and pineal gland. Rus. Newsl. Obstetr. and Gynecol. 2012;12(6):29-34.
18. Arushanian E. B. Importance of pineal hormone melatonin in pediatria and pediatric pharmacology. Med. Newsl. North Caucasus. 2012;1:116-122.
19. Arushanian E. B. Therapeutic capacity of pineal hormone melatonin in cerebral trauma. J. Neurol. and Psychiat. 2012;112(11):73-78.
20. Arushanian E. B. Modern knowledge of circadian fluctuations in cardiovascular system, in norm and pathology. Clin. Med. 2012;4:11-18.
21. Arushanian E. B. Experimental and clinical evidences to anticonvulsive activity of melatonin. J. Neurol. and Psychiat. 2013;113(11):112-116.
22. Arushanian E. B. Influence of melatonin on thrombocytes homeostasis and its circadian organization. Exp. and Clin. Pharmacol. 2013;76(5):32-38.
23. Arushanian E. B. Protective effect of melatonin on erythrocyte function. Med. Newsl. North Caucasus. 2013;8(3):95-100.
24. Arushanian E. B. Pineal gland in pediatria: the role of pineal hormone melatonin in the genesis of autism. Med. Newsl. North Caucasus. 2013;8(2):82-85.
25. Arushanian E. B., Arushanian L. G., Elbekyan K. S. Place of pineal-adrenocortical relations in corrective regulation of behavior. Adv. Physiol. Sciences. 1993;24:73-79.
26. Arushanian E. B., Beyer E. V. Immunotropic features of pineal melatonin Exp. and Clin. Pharmacol. 2002;63(5):73-80.
27. Arushanian E. B., Beyer E. V. Brain pineal gland hormone melatonin and cardiovascular system. Part 1. Melatonin impact on blood pressure in norm and pathology. Med. Newsl. North Caucasus. 2011;1:69-73.
28. Arushanian E. B., Beyer E. V. Brain pineal gland hormone melatonin and cardiovascular system. Part 2. Melatonin impact on heart functions in norm and pathology. Med. Newsl. North Caucasus. 2011;2:90-95.
29. Arushanian E. B., Karakov K. G., Elbekyan K. S. Thera- peutic effect of melatonin in oral cavity disorders. Exp. and Clin. Pharmacol. 2012;75(6):48-52.
30. Arushanian E. B., Mastyagina O. A. Melatonin in cardiovascular system and its pharmacological regulation. Exp. and Clin. Pharmacol. 2008;71(3):65-71.
31. Arushanian E. B., Naumov S. S. Stroke and pineal gland. J. Neurol. and Psychiat. 2009;109:67-74.
32. Arushanian E. B., Naumov S. S. Anti-inflammatory potential of melatonin. Clin. Med. 2013;7:18-22.
33. Arushanian E. B., Naumov S. S., Ponomareva V. A. Protective influence of melatonin on behavioral and morphological disorders caused by cerebral trauma in rats at different time of day. Exp. and Clin. Pharmacol. 2009;72(3):18-21.
34. Arushanian E. B., Ovanesov K. B. Role of pineal gland in pathogenesis of psychical depression. J. Higher Nerv. Act. 1991;41:822-827.
35. Arushanian E. B., Ovanesov K. B., Ovanesova I. M.
Comparative impact of melatonin and bilobil on photoreception and psycophysiological indices in patients with cerebral trauma. Exp. and Clin. Pharmacol. 2007;70(2):20-23.
36. Jerieva I. S., Volkova N. I. Nitrooxidative stress and its potential correction with melatonin. – Melatonin: potential use in clinical practice. Мoscow: «Imapress»; 2012. P. 125-134.
37. Kvetnoy I. M., Kvetnaya T. V., Raikhlin N. T. Extrapineal melatonin: place and role in homeostasis neuroendocrine regulation. – Melatonin in norm and pathology. Мoscow: «Medpractica»; 2004. P. 34-47.
38. Malinovskaya N. K., Komarov F. I., Rapoport S. I. et al. Melatonin and cardiovascular system. – Melatonin in norm and pathology. Мoscow: «Medpractica»; 2004. P. 85-101.
39. Malinovskaya N. K., Komarov F. I., Rapoport S. I. Mela- tonin in treating duodenal ulcer. – Melatonin in norm and pathology. Мoscow: «Medpractica»; 2004. P. 146-162.
40. Ambriz-Tufuti M., Rocha-Gonzalez H., Cruz S. L. et al. Melatonin: a hormone that modulates pain. Life Sci. 2009;84:489-498.
41. Ardura J., Andres J., Gaemendia J. R. Melatonin in epilepsy and febrile seizures. J. Child. Neurol. 2010;25:888- 891.
42. Ayer R. E., Sugawara T., Zhang J. H. Effects of melatonin in early brain injury following subarachnoid hemorrhage. Acta Neurochir. 2008;102(Suppl.):329-330.
43. Bagci S., Horoz O., Yidizdas D. et al. Melatonin status in pediatric intensive care patients with sepsis. Pediatr. Crit. Care Med. 2012;13:e120-e123.
44. Banach M., Gurdziel E., Jedrych M. Melatonin in experimental seizures and epilepsy. Pharmacol. Rep. 2011;63:1-11.
45. Bayir A., Kiresi D.A., Kara H. et al. The effects of mannitol and melatonin on MRI findings in an animal model of traumatic brain edema. Acta Neurol. Belg. 2008;108:149-154.
46. Brzozowska P., Ptah-Belowska S., Pavlik M. et al. Mucosal strengthening activity of central and peripheral melatonin in the mechanism of gastric defense. J. Physiol. Pharmacol. 2009;60:47-56.
47. Bubenik G. A. Thirty four years since the discovery of gastrointestinal melatonin. J. Physiol. Pharmacol. 2008;59(Suppl. 2):33-51.
48. Cardinali D. P., Alvarez C. B. Melatonin in Chagas’ disease. Possible therapeutic value. Medicine. 2011;71:477-483.
49. Carrillo-Vico A., Reiter R. J., Lardone P. J. et al. The modulatory role of melatonin on immune responsiveness. Curr. Opin. Investig. Drugs. 2006;7:423-431.
50. Celinski K., Konturek P. C., Konturek S. J. et al. Effect of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori. J. Physiol. Pharmacol. 2011;62:521-526.
51. Choinacki C., Wisniewska-Jaroinska M., Walecka-Kapicaer et al. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J. Physiol. Phar- macol. 2011;62:327-334.
52. Col C., Dinler K., Hasdemir O. et al. Exogenous melatonin treatment reduces hepatocyte damage in rats with experimental acute pancreatitis. J. Hepatobilliary Pancreat. Sci. 2010;17:682-687.
53. Cutando A., Aneiros-Fernandez J., Aneiros-Cachaza J. Melatonin and cancer: current knowledge and its application to oral cavity tumors. J. Oral. Pathol. Med. 2011;38:164-175.
54. Dominguez-Rodriguez A. Melatonin in cardiovascular disease. Expert. Opin. Investig. Drugs. 2012;21:1593- 1596.
55. Esposito E., Patriniti I., Mazzon E. et al. Melatonin reduces hyperalgesia associated with inflammation. J. Pineal Res. 2010;49:321-331.
56. Gitto E., Pellegrino S., Gitto P. et al. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J. Pineal. Res. 2009;46:128-139.


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy